Media

  • Home
  • About Us
  • Products + Pipeline
    • About Cenobamate
  • Healthcare Professionals
  • About Epilepsy
  • Careers
  • Media
    • Press Release
    • Events
  • Contact
  • News + Press Releases
  • Events
  • 2021
  • 2020
  • 2019

Appointment of Dr Otto Schwarz as Independent Director and Chairman of the Board

Zug, Switzerland, December 4, 2019 – Arvelle Therapeutics GmbH (“Arvelle”), an emerging biopharmaceutical company focused on bringing…

Press Release December 4, 2019

SK Life Science, Inc. Receives US FDA Approval for cenobamate tablets for the Treatment of Partial-Onset Seizures in Adults with Epilepsy

Approval based on pivotal trials that assessed the efficacy and safety of cenobamate Arvelle Therapeutics has exclusive rights to develop and…

Press Release November 25, 2019

Arvelle Therapeutics wins Series A Finance Raise of the Year Award

Zug, Switzerland, November 20, 2019 – Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing innovative treatments to…

Press Release November 20, 2019

Results of Randomized Study Evaluating the Safety and Efficacy of Cenobamate in Patients with Uncontrolled Focal-Onset Epilepsy Published in The Lancet Neurology

Cenobamate significantly reduced focal seizure frequency, with as many as 20% of patients reaching zero seizures during the study’s maintenance…

Press Release November 14, 2019

Arvelle Therapeutics Strengthens Management Team with Key New Hires

Appoints Petra Molan as Senior Vice President Commercial and Enrico Dolfini as Vice President Legal Counsel Full leadership team now in place ahead…

Press Release October 31, 2019

Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe

Arvelle Therapeutics GmbH to provide SK Biopharmaceuticals an upfront payment of $100 million with future milestone potential of up to $430 million A…

Press Release February 14, 2019

Related Articles


  • The Lancet Neurology

    November 13, 2019
    Results of Randomized Study Evaluating the Safety and Efficacy of Cenobamate in Patients with Uncontrolled Focal-Onset Epilepsy Published
  • Bioworld

    November 4, 2019
    Arvelle’s CEO Mark Altmeyer Interview
+41 44 5672940 info@arvelletx.com

Arvelle Therapeutics
International GmbH
Zählerweg 6,
6301 Zug, Switzerland

LinkedIn LinkedIn Twitter Twitter
  • Home
  • Privacy Policy